Helping the prevention and treatment of hepatitis C, the medical application system of Yunnan patient management system

Recently, the film "I am not a drug god" has made "leukemia treatment" a public focus, and with the price of anti-cancer drugs such as Gleevec and the list of medical insurance, the burden of medical care for patients with severe diseases such as leukemia and cancer is becoming obvious. Reduced.

However, compared with these dangerous and fatal diseases, some hidden "invisible killers" have not received enough attention. The typical example is hepatitis C. World Hepatitis Day is approaching on July 28, but hepatitis C is still out of public view.

Hepatitis C, the "invisible killer" with very low recognition

Hepatitis C has a low public awareness, low diagnostic rate, and low treatment rate. This is a fact recognized by many people in the industry.

It is understood that the hepatitis C infection rate in China is about 0.7%, and the infected population is about 9.8 million. However, by 2016, only about 1.17 million people were diagnosed, accounting for less than 12% of all patients.

Relative to the public "talking about cancer discoloration", when it comes to hepatitis C, most people think that it is far from their own lives. The early symptoms of hepatitis C are not obvious, not easy to detect, and patients are concentrated in remote areas of rural areas. The health consciousness is weak, often after 10-20 years, the condition deteriorates, and cirrhosis and even liver cancer will appear in serious cases. Missed the best treatment opportunity.

In addition, the diagnosis of hepatitis C requires nucleic acid testing, and county-level primary hospitals often do not have the corresponding detection capabilities, which is also a major reason for the high rate of missed diagnosis of hepatitis C.

Fortunately, hepatitis C is a curable disease. But economic reasons are still an important reason for hindering patients to receive effective treatment. “There are often small advertisements for purchasing generic drugs in hospitals.” A medical worker who was on the front line of hepatitis C treatment told reporters.

In fact, the treatment of hepatitis C is different from leukemia. Can generic drugs really replace the original drug? In this regard, the reporter interviewed Yue Wei, deputy director of the Department of Infectious Diseases of the First People's Hospital of Yunnan Province.

Yue Wei, deputy director of the Department of Infectious Diseases, First People's Hospital of Yunnan Province

Director Yue Wei pointed out: "Purchasing is not only possible to buy fake medicines, but there are 6 genotypes of hepatitis C. It is easy to choose the wrong medicine when purchasing. In addition, some patients have just stopped seeing the effect and the treatment is not complete. Some will also encounter Adverse reactions, if you don't have the doctor's guidance, don't know how to deal with them. Therefore, it is not recommended to buy drugs through informal channels."

Therefore, the treatment of hepatitis C must return to the formal medical institutions, using the original drug. For the poor, the China Primary Health Care Foundation teamed up with Gilead Science to launch the “Chongqing Hehe Hepatitis C” assistance project earlier this year.

The project will cover more than 200 hospitals in 51 cities, and the first batch will benefit more than 4,000 patients with low-income and low-income hepatitis C. Patients with subsistence allowances can apply for free medication, while low-income patients (family annual income <150,000) can apply for three-plus-three assistance.

Director Yue Wei said that four of his patients had low-income patients and more than 20 low-income patients applied for assistance.

The complicated process of hepatitis C diagnosis and treatment is also a big burden for patients. It is understood that the patient has to go through five or six hospitals from the initial screening to undergo multiple examinations to confirm the diagnosis, and the subsequent treatment process is even more difficult. The hepatitis C patients are mostly in remote rural areas, and the transportation, accommodation and other expenses brought about by medical treatment should not be underestimated. "Eat medicine is expensive" can seek public welfare assistance, and it is even more difficult to solve the problem of "difficult to see a doctor." However, with the rise of Internet technology, new technologies are quietly changing the traditional medical treatment model, providing new ideas for solving the "difficult to see a doctor."

In the “Up and Down, Healing Hepatitis C” assistance project, Gilead’s strategic partner, the leading medical solution provider in China, relies on one-stop patient management services to realize remote referral, electronic prescription, and drug delivery to home services. The closed loop solves multiple pain points in the medical treatment process.

Director Yue Wei believes that the establishment of patient files through the Medical Network Internet platform greatly facilitates the management of patients by doctors. At the same time, the Internet platform has also played an important role in the promotion and education of patients, and established a good communication channel between doctors and patients, which helps patients actively cooperate with treatment.

More importantly, it reduces the number of patients going to and from the hospital and reduces the financial burden on patients. In the aid project of Gilead, doctors can use the medical association platform to prescribe online, and drugs can be sent directly to some remote areas, making it easier for doctors to see a doctor and benefit patients. And through a formal platform like the Medical Association, patients can also avoid buying fake drugs.

Hepatitis C prevention and treatment, the government needs to take the lead, social security support

Of course, to meet the treatment needs of 9.8 million patients, it is impossible to rely solely on non-profit organizations, caring enterprises, scientific and technological means, and medical institutions. It is also necessary to attach great importance to the effective top-level design at the policy level, open the green channel for drug approval, and shorten the time limit for approval. Reducing circulation links, country-led price negotiations, and importing imported patented drugs into health care will greatly improve the treatment predicament of hepatitis C patients in China.

Public awareness needs to be improved is also the focus of industry experts.

Because hepatitis C is mainly transmitted through blood, mother-infant, sexual contact, etc., it is urgent to guide high-risk groups to conduct independent screening, and medical institutions must take the initiative to attack. At present, the team of Director Yue Wei has tried to penetrate the grassroots level to carry out screening and education for high-risk groups of hepatitis C, and is establishing an overall prevention and treatment model for screening, education, referral, treatment and follow-up.

In the upcoming "World Hepatitis Day", Director Yue Wei expects that hepatitis C can be fully publicized and further known by the public. "After all, hepatitis C is a contagious disease. If it is not given enough attention, the social harm will be great."

According to the World Health Organization (WHO) proposed 2030 hepatitis C control goal: the basic elimination of hepatitis C hazard, the screening rate for high-risk groups should reach 90%, the treatment rate is greater than 70%. To achieve this goal, there is still a long way to go. It requires the joint efforts and unremitting efforts of governments at all levels, medical institutions, pharmaceutical companies, non-profit organizations, technology platforms, and news media.

SARS-CoV-2 Neutralizing Antibody Rapid Test (Golloidal Gold)

SARS-CoV-2 Neutralizing Antibody,COVID-19 Antibody,Golloidal Gold,Rapid Test

Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimedicadevice.com